Aslan Fred 4
4 · Artiva Biotherapeutics, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Aslan Fred
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-12-12+869,136→ 1,213,135 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−100,577→ 0 totalExercise: $5.01Exp: 2031-02-23→ Common Stock (100,577 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−51,463→ 0 totalExercise: $5.01Exp: 2030-12-17→ Common Stock (51,463 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−257,319→ 0 totalExercise: $5.01Exp: 2030-12-17→ Common Stock (257,319 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−26,450→ 0 totalExercise: $5.18Exp: 2034-01-23→ Common Stock (26,450 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−113,999→ 0 totalExercise: $13.47Exp: 2034-05-01→ Common Stock (113,999 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−319,331→ 0 totalExercise: $12.00Exp: 2034-07-17→ Common Stock (319,331 underlying)
Footnotes (6)
- [F1]Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
- [F2]On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
- [F3]25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F4]25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F5]Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
- [F6]25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.